Barry Greene Seizes CNS Leadership Opportunity As New Sage CEO

Jeff Jonas Remains As Chief Innovation Officer, Board Member

When Greene made the decision to leave Alnylam, he was interested in working with a drug maker treating central nervous system diseases.

Barry Greene
Barry Greene's first day as Sage CEO was 15 December • Source: Sage Therapeutics Inc.

Barry Greene was interested in pursuing opportunities related to central nervous system diseases when the long-time Alnylam Pharmaceuticals Inc. president made the decision to move on. Already familiar with Sage Therapeutics, Inc. and unable to take a long vacation between executive gigs due to the COVID-19 pandemic, Greene told Scrip, the opportunity to lead CNS drug developer Sage as its new CEO was a “no-brainer” – pun intended.

Greene’s new role was revealed on 16 December, but Sage’s prior CEO Jeff Jonas isn’t going anywhere. Jonas will remain...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Leadership

More from Scrip